Other Clinical Trial - 5-day Defibrotide Treatment for Hepatic SOS/VOD

Status Recruiting

Clinical Trial Summary

Sinusoidal Obstruction Syndrome (SOS), also referred to as hepatic veno-occlusive disease (VOD), is rare but serious complication of allogeneic stem cell transplantation (allo-SCT). Defibrotide is the only FDA approved therapy to treat SOS and has significantly improved outcomes. When applied early, SOS symptoms often quickly improve and an abbreviated course can be applied. This study is looking at an abbreviated 5 day course of defibrotide in those patients with a complete response to therapy with the primary outcome being day 100 overall survival as compared to history data.

Clinical Trial Description

Sinusoidal obstructive syndrome (SOS) has a reported mean incidence of 13.7% and even among those undergoing reduced intensity conditioning regimens is approximately 9%. SOS is a clinical syndrome characterized by painful hepatomegaly, jaundice, ascites, fluid retention, and weight gain. The onset is usually before day 35 after stem cell infusion. SOS ranges in severity from a mild reversible disease to a severe syndrome associated with multiorgan failure (MOF) and death. Prior to the introduction of defibrotide, severe SOS was nearly universally fatal with a mortality rate approaching 100% by day 100 after allo-SCT. The diagnosis of SOS/VOD is clinical and should be considered in any patient who has undergone hematopoietic stem cell transplantation and develops liver dysfunction. Patients with mild or moderate disease have reasonably good outcomes with supportive therapy alone while in contrast prognosis is much worse in severe SOS which occurs in about 25-30% cases. Defibrotide is the only established Food and Drug Administration (FDA) approved therapy to treat SOS. It is now approved for use in adults and children with SOS with renal or pulmonary dysfunction following HCT. The standard treatment is 25 mg/kg/day in 4 divided doses of 6.25 mg/kg for 21 days. However, responses are frequently brisk and complete in many patients thus it has been postulated that in responding patients this treatment course could be abbreviated given the risk for adverse events such as hypotension/shock and hemorrhage. This is an open label pilot study evaluating an abbreviated 5 (as compared to 21) day course of defibrotide in patients with confirmed SOS. The primary outcome is day 100 survival as compared to historical data. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04313036
Study type	Interventional
Source	Loyola University
Contact	Patrick A Hagen, MD, MPH
Phone	708-327-3157
Email	patrick.hagen@lumc.edu
Status	Recruiting
Phase	Phase 2
Start date	March 11, 2021
Completion date	August 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05611307` - Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Recruiting	`NCT03818334` - Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies	Phase 2/Phase 3
Withdrawn	`NCT05895201` - High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD	Phase 1/Phase 2
Completed	`NCT04687982` - Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).	N/A
Recruiting	`NCT06416761` - Genetics in the Progression of Nephropathies
Completed	`NCT03858530` - Ultrasound Elastography to Predict Development of SOS	Phase 4
Completed	`NCT03200626` - Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma
Recruiting	`NCT05709912` - Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant	N/A
Completed	`NCT05175222` - Assessment of Efficacy of LightWalker (Nd:Yag, Er:Yag) Laser Therapy on Incidence, Severity and Duration of Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT). Prospective Randomized Open-label Study	N/A
Recruiting	`NCT05316740` - Vaginal Microbiome and the Development of Vulvovaginal Graft Versus Host Disease
Recruiting	`NCT05629676` - Virtual Reality Intervention for Patients Undergoing BMT	N/A
Recruiting	`NCT05694910` - Reiki Effects on Bone Marrow Transplant Patients	N/A
Completed	`NCT05352789` - Nutrition and Metabolic Prehabilitation in HSCT Patients UK and ROI. BSBMT Multi-centre Survey.
Withdrawn	`NCT03963999` - Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients	Phase 4
Recruiting	`NCT03865589` - Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.